© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Femasys Inc. (FEMY) stock surged +1.19%, trading at $2.56 on NASDAQ, up from the previous close of $2.53. The stock opened at $2.55, fluctuating between $2.55 and $2.69 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | 2.57 | 2.63 | 2.53 | 2.53 | 32.29K |
| Sep 18, 2026 | 2.51 | 2.64 | 2.51 | 2.59 | 35.03K |
| Sep 17, 2026 | 2.56 | 2.61 | 2.45 | 2.55 | 64.95K |
| Sep 16, 2026 | 2.61 | 2.74 | 2.51 | 2.54 | 79.41K |
| Sep 15, 2026 | 2.67 | 2.74 | 2.50 | 2.56 | 71.17K |
| Sep 14, 2026 | 2.84 | 2.85 | 2.59 | 2.67 | 29.81K |
| Sep 11, 2026 | 2.81 | 2.83 | 2.74 | 2.78 | 16.2K |
| Sep 10, 2026 | 2.90 | 2.95 | 2.68 | 2.74 | 35.53K |
| Sep 09, 2026 | 2.71 | 2.84 | 2.67 | 2.83 | 46.6K |
| Sep 08, 2026 | 2.99 | 3.09 | 2.60 | 2.68 | 197.74K |
| Sep 04, 2026 | 3.03 | 3.06 | 2.93 | 2.98 | 72.92K |
| Sep 03, 2026 | 3.10 | 3.18 | 3.01 | 3.06 | 0 |
| Sep 02, 2026 | 3.26 | 3.39 | 3.02 | 3.10 | 138.71K |
| Sep 01, 2026 | 3.34 | 3.43 | 3.21 | 3.26 | 66.8K |
| Aug 31, 2026 | 3.22 | 3.44 | 3.10 | 3.43 | 230.51K |
| Aug 28, 2026 | 2.79 | 3.35 | 2.74 | 3.20 | 527.15K |
| Aug 27, 2026 | 2.93 | 3.09 | 2.73 | 2.79 | 189.75K |
| Aug 26, 2026 | 2.88 | 3.00 | 2.83 | 2.92 | 110.78K |
| Aug 25, 2026 | 3.00 | 3.06 | 2.81 | 2.85 | 211.09K |
| Aug 24, 2026 | 2.94 | 3.08 | 2.86 | 2.98 | 293.06K |
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
| Employees | 53 |
| Beta | -2.07 |
| Sales or Revenue | $1.07M |
| 5Y Sales Change% | -0.118% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |